Breaking News Instant updates and real-time market news.

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

12:28
09/19/17
09/19
12:28
09/19/17
12:28

Michigan AG says 41 state attorneys general now involved in opioid probe

Michigan Attorney General Bill Schuette announced that he is moving forward with an investigation of both the manufacturers and the distributors of prescription opioid drugs alongside a bipartisan coalition of 41 state attorneys general, stating that today's announcement "represents a dramatic expansion and coordination of the investigations by the attorneys general into the nationwide opioid epidemic." The coalition has demanded detailed information and documents from both the manufacturers and the distributors. The attorneys general are actively investigating the following pharmaceutical manufacturers and their related entities: Endo International (ENDP), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Teva Pharmaceutical (TEVA), Allergan (AGN) and Purdue Pharma. The attorneys general are also seeking documents and information about distribution practices from the following medical prescription distribution companies: AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK).

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.49

-3.05 (-1.38%)

ABC

AmerisourceBergen

$80.20

-0.47 (-0.58%)

CAH

Cardinal Health

$66.36

-0.71 (-1.06%)

MCK

McKesson

$149.89

1.47 (0.99%)

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

ENDP Endo
$8.34

-0.26 (-3.02%)

09/07/17
JEFF
09/07/17
NO CHANGE
Target $15
JEFF
Buy
Collegium valuation 'looks very attractive,' says Jefferies
Jefferies analyst David Steinberg says shares of Collegium Pharmaceutical (COLL) have been weak despite the acceleration of Xtampza prescription trends since June. With the company likely on track to exceed expectations, the valuation at current share levels "looks very attractive," Steinberg tells investors in a research note. He also believes the benefit from Endo's (ENDP) Opana market withdrawal may start kicking in soon. The analyst keeps a Buy rating on Collegium with a $15 price target.
08/16/17
SBSH
08/16/17
UPGRADE
Target $42
SBSH
Buy
Mylan upgraded to Buy from Neutral at Citi
Citi analyst Liav Abraham upgraded Mylan (MYL) to Buy and raised her price target for the shares to $42 from $36. The company is best positioned to execute in a challenging operating environment for generics, Abraham tells investors in a research note. Mylan has a "differentiated and durable" generics product portfolio, "broad pipeline" of complex generics/ biosimilars and a more favorable balance sheet profile relative to peers, the analyst contends. She has Neutral ratings on Teva (TEVA) and Endo (ENDP).
07/24/17
JANY
07/24/17
NO CHANGE
Target $4
JANY
Buy
BioDelivery Sciences price target raised to $4 from $3 at Janney Capital
Janney Capital analyst Ken Trbovich sees multiple reasons to expect BioDelivery Sciences' Belbuca growth above current levels, including the continued maturing of its newer sales people, the opportunity to secure Medicare coverage contracts and Endo's (ENDP) recent decision to remove Opana ER from the market. He raised his fair value estimate on BioDelivery to $4 from $3 and keeps a Buy rating on the stock.
06/16/17
CANT
06/16/17
INITIATION
Target $12
CANT
Neutral
Endo initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Endo International with a Neutral rating and $12 price target.
JNJ Johnson & Johnson
$134.95

-0.43 (-0.32%)

08/02/17
PIPR
08/02/17
NO CHANGE
Target $7
PIPR
Overweight
Imbruvica approval in graft versus host positive for Kadmon, says Piper Jaffray
After the FDA expanded the approval of AbbVie (ABBV) and Johnson & Johnson's (JNJ) Imbruvica for the treatment of adults with chronic graft versus host disease, or cGVHD, Piper Jaffray analyst Edward Tenthoff said he views the news as positive for Kadmon's KD025. Imbruvica is tough for patients to tolerate, said Tenthoff, who sees an opportunity for KD025 to more safely treat cGVHD patients. He keeps an Overweight rating and $7 price target on Kadmon shares.
08/14/17
BTIG
08/14/17
UPGRADE
Target $100
BTIG
Buy
Masimo upgraded to Buy, could be acquired by Johnson & Johnson, says BTIG
BTIG analyst Sean Lavin upgraded Masimo (MASI) to Buy from Neutral with a $100 price target saying he is more bullish on the Philips (PHG) agreement leading to increased revenue and margins, and the recent share pullback has provided a buying opportunity. Lavin said Masimo has been executing "superbly" and believes the Philips' relationship will drive acceptance of hemoglobin and Rainbow. Further, the analyst thinks Johnson & Johnson (JNJ) could be an acquirer of Masimo as it sells its products into the OR and ICU markets and would "massively" expand operating margins, and notes Philips may see the value of Masimo's products and make a bid.
08/16/17
JPMS
08/16/17
NO CHANGE
Target $148
JPMS
Overweight
Johnson & Johnson price target raised ahead of ESC meeting at JPMorgan
JPMorgan analyst Michael Weinstein raised his price target for Johnson & Johnson shares to $148 from $140 ahead of the European Society of Cardiology beginning on August 26. The big event for J&J is the presentation of the COMPASS trial, investigating the use of Xarelto for the treatment of coronary or peripheral artery disease, Weinstein tells investors in a research note. His statistical analysis suggests a minimum 25% reduction in major adverse cardiac events, or MACE. This would make COMPASS a "landmark event in the treatment of CAD/PAD" and lead to Xarelto being adopted as the new standard of care in this greater than $5B indication, Weinstein writes. He recommends buying J&J shares ahead of the European Society of Cardiology meeting and keeps an Overweight rating on the name.
08/31/17
UBSW
08/31/17
NO CHANGE
Target $148
UBSW
Buy
Johnson & Johnson remain a top pick, says UBS
UBS analyst Matt Miksic met with Johnson & Johnson management and came away remaining confident in his conviction of his bullish view on the company. The analyst sees sustained Pharma growth, stable Med Device growth and an improving Consumer division. He identifies multiple drivers, including its pipeline and potential deal interest in Eye Care, Dental, Structural Heart and Neurology. Miksic reiterated his Buy rating and $148 price target on the stock, adding Johnson & Johnson remains a top pick.
TEVA Teva
$17.14

0.15 (0.88%)

09/12/17
WELS
09/12/17
NO CHANGE
WELS
Cooper Companies Paragard IUD deal not cheap but 'good fit,' says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that Cooper Companies (COO) announced that it will acquire Paragard IUD from Teva (TEVA) for $1.1B cash and expects the transaction to close by the end of CY17. The analyst believes that while deal is not cheap, it appears to be a "good strategic fit." Further, he sees the acquisition as accretive to margins but not sales growth.
09/18/17
RBCM
09/18/17
NO CHANGE
RBCM
Teva price target lowered to $15 from $21 at RBC Capital
RBC Capital analyst Randall Stanicky cut his price target on Teva as he believes that the new CEO will need time "to come up to speed," and the analyst is unsure what strategic options the new CEO can take that the board has not already considered. Stanicky says that the company's debt load "looks severe," while it faces multiple additional headwinds, including generic Copaxone and headwinds to its own generic business. He cut his price target on the shares to $15 from $21 and keeps an Underperform rating on the name.
09/19/17
CANT
09/19/17
NO CHANGE
Target $17
CANT
Neutral
Teva divestitures should remove covenant risk, says Cantor
Cantor Fitzgerald analyst Louise Chen says the valuation Teva Pharmaceutical received for its women's health franchise assets is higher than the Street expected. The sale should enable Teva to pay down sufficient debt to remain in compliance with its covenants at year end, Chen wrote yesterday in a research note. She believes the news should remove an overhang on the stock. The analyst keeps a Neutral rating on Teva with a $17 price target.
09/19/17
WELS
09/19/17
NO CHANGE
WELS
Market Perform
Assets sale a 'step in right direction' for Teva, says Wells Fargo
Wells Fargo analyst David Maris notes that Teva announced that it has entered into two separate agreements to sell the remaining assets in its specialty global women's health business for an aggregate of $1.38B. While the sale is a step in the right direction for Teva, the analyst notes that the proceeds amount to only small step toward lowering Teva's approximate $35B in debt. He reiterates a Market Perform rating on the shares.
AGN Allergan
$218.49

-3.05 (-1.38%)

09/18/17
JPMS
09/18/17
NO CHANGE
Target $300
JPMS
Overweight
Allergan shares offer ' increasingly compelling setup,' says JPMorgan
JPMorgan analyst Chris Schott sees an "increasingly compelling setup" for shares of Allergan following the 14% pullback since before the Q2 earnings report. Several controversies, most notably the timing of generic Restasis competition, have taken focus away from a "highly attractive" core franchise, Schott tells investors in a research note. The analyst believes the financial risk of generic Restasis competition is "manageable and fairly well quantified." He sees pipeline optionality and a "strong" sum-of-the-parts valuation argument at current share levels. Allergan represents one of the analyst's top picks. Schott has an Overweight rating on the shares with a $300 price target.
09/08/17
ROTH
09/08/17
NO CHANGE
Target $13.25
ROTH
Buy
Roth Capital 'cautiously optimistic' on Avadel's deal for Noctiva
Roth Capital analyst Scott Henry said he is "cautiously optimistic" on Avadel's (AVDL) deal to acquire U.S./Canadian rights for Noctiva, though he notes concerns, such as this drug needing an expensive, market-creating type of promotion and the fact that Allergan (AGN) walked away from a prior deal for Noctiva after its approval. He lowered his price target on Avadel to $13.25 from $15 to reflect lower cash post this acquisition, but keeps a Buy rating, citing his positive view on the sodium oxybate program.
09/08/17
WELS
09/08/17
NO CHANGE
WELS
Outperform
Allergan patent deal 'innovative and unexpected positive,' says Wells Fargo
Wells Fargo analyst David Maris calls Allergan's agreement with the Saint Regis Mohawk Tribe an "innovative and unexpected positive move." The agreement should eliminate the threat, and an "important overhang" on the shares, of the inter partes review on Restasis, one of Allergan's largest products, Maris tells investors in an intraday research note. He has an Outperform rating on the shares. The Botox maker is up 2% to $232.40 in afternoon trading.
09/12/17
DBAB
09/12/17
NO CHANGE
Target $262
DBAB
Buy
Allergan price target lowered to $262 from $278 at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert lowered his price target for Allergan shares to $262 but maintains a Buy rating on the name. The lowered his sales estimates for Viberzi, Linzess, Aczone, and several other products based on based on recent IMS volume trends. Gilbert, however, continues to view Allergan as a "reasonably valued stock with an attractive growth profile."
ABC AmerisourceBergen
$80.20

-0.47 (-0.58%)

09/14/17
MSCO
09/14/17
DOWNGRADE
Target $91
MSCO
Equal Weight
AmerisourceBergen downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Ricky Goldwater downgraded AmerisourceBergen (ABC) and McKesson (MCK) to Equal Weight from Overweight saying EBIT growth is at risk from increased generic price inflation and a record number of generic drug approvals in the next two years. Goldwater changed his thesis and does not believe pricing pressure will abate soon due to continued generic deflation and increased customer access to pricing information. He thinks it is increasingly likely that one or more distributors "blinks" on price, hurting economics. Goldwater lowered AmerisourceBergen's price target to $91 from $94 and McKesson's price target to $172 from $184.
09/14/17
LEER
09/14/17
NO CHANGE
LEER
Minimal hurricane exposure for pharma supply chain, says Leerink
Leerink analyst David Larsen sees less than 1% impact to revenues and earnings to companies in his coverage from Hurricane Harvey and Irma and believes any effects will be viewed as one-time in nature. The analyst notes that "the percentage of state impacted" and "days of impact" are particularly challenging variables in his model to estimate, but based on various assumptions he believes the hurricanes will prove to be a minor event for Express Scripts (ESRX), AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK). Nonetheless, Larsen says pharmacy retailers Walgreens Boots Alliance (WBA) and CVS Health (CVS) may face some store closures and possible damage costs.
09/14/17
09/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hertz (HTZ) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Adam Jonas citing the doubling of shares over the last three months and raised its price target to $14 from $12. 2. New Oriental Education (EDU) downgraded to Underweight from Neutral at JPMorgan with analyst Leon Chik saying the downgrade is "purely a valuation call." 3. McKesson (MCK) and AmerisourceBergen (ABC) were downgraded to Equal Weight from Overweight at Morgan Stanley. 4. Apache (APA) and Imperial Oil (IMO) were downgraded to Underweight from Neutral at JPMorgan, while Hess Corp. (HES) was downgraded to Neutral from Overweight. 5. Ryanair (RYAAY) downgraded to Reduce from Hold at HSBC with analyst Andrew Lobbenberg citing the ECJ ruling against the company's practice of employing flight crew on Irish labor contracts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
AmerisourceBergen initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of AmerisourceBergen with an $87 price target and a Sector Perform rating.
CAH Cardinal Health
$66.36

-0.71 (-1.06%)

09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Cardinal Health initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Cardinal with a $72 price target and a Sector Perform rating.
08/03/17
FBCO
08/03/17
NO CHANGE
Target $81
FBCO
Outperform
Cardinal Health price target lowered to $81 from $87 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for Cardinal Health to $81 from $87, citing on a "surprising" cut to 2018 EPS guidance primarily on incremental investment initiatives across its businesses, further defining 2018 as a transition year. The analyst reiterates an Outperform rating on the shares.
08/09/17
BARD
08/09/17
NO CHANGE
BARD
Neutral
AmerisourceBergen settlement ups odds of PharMerica switch, says Baird
Baird analyst Eric Coldwell said AmerisourceBergen's (ABC) 10-Q last week showed that the company and PharMerica (PMC) have tentatively agreed to settle their long-running legal fight, which he reads as significantly increasing the odds of AmerisourceBergen displacing incumbent Cardinal Health (CAH) after KKR (KKR) and minority investor Walgreens (WBA) complete their deal to buy PharMerica. Coldwell has a Neutral rating and $89 price target on AmerisourceBergen shares.
MCK McKesson
$149.89

1.47 (0.99%)

09/19/17
BARD
09/19/17
UPGRADE
BARD
Outperform
McKesson upgraded to Outperform from Neutral at Baird
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
McKesson initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of McKesson with a $168 price target and a Sector Perform rating.
09/19/17
09/19/17
UPGRADE
Target $178

Outperform
McKesson upgraded to Outperform on 'trading call' at Baird
As previously reported, Baird analyst Eric Coldwell upgraded McKesson to Outperform from Neutral, calling his rating change a "tactical/trading call" following the shares' material underperformance, both year-to-date and over the last twelve months. Over 80% of analysts are neutral/negative and consensus estimates across distributors are starting to make sense, he tells investors, adding that McKesson is building a "much more balanced" model. Coldwell raised his price target on the stock to $178 from $175.
09/19/17
09/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Gap (GPS) upgraded to Neutral from Underperform at Credit Suisse analyst Christian Buss saying his firm's brick-and-mortar real estate analysis indicates Gap is better positioned than he thought. 2. Michael Kors (KORS) upgraded to Outperform from Perform at Oppenheimer with analyst Anna Andreeva saying the turnaround in retail is just starting, while sentiment on the shares is "extremely negative." 3. McKesson (MCK) upgraded to Outperform from Neutral at Baird with analyst Eric Coldwell calling his rating change a "tactical/trading call" following the shares' material underperformance, both year-to-date and over the last twelve months. 4. NetApp (NTAP) upgraded to Buy from Neutral at UBS with analyst Steven Milunovich saying NetApp's product position is improved with a re-write of its storage software contributing to all-flash success. 5. Knight-Swift (KNX) resumed with a Buy from Neutral at Citi with analyst Christian Wetherbee saying the truck market recovery appears to be accelerating in the second half of 2017, and Knight-Swift is best levered to an improving truckload market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SYNT

Syntel

$24.30

5.2 (27.23%)

20:37
10/17/17
10/17
20:37
10/17/17
20:37
Upgrade
Syntel rating change  »

Syntel upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 14

    Dec

QD

Qudian

20:35
10/17/17
10/17
20:35
10/17/17
20:35
Syndicate
Qudian 37.5M share IPO priced at $24.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ABT

Abbott

$55.06

0.43 (0.79%)

, USB

U.S. Bancorp

$53.88

-0.38 (-0.70%)

20:25
10/17/17
10/17
20:25
10/17/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$55.06

0.43 (0.79%)

USB

U.S. Bancorp

$53.88

-0.38 (-0.70%)

SVU

Supervalu

$19.38

0.57 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 17

    Jan

UNH

UnitedHealth

$203.89

10.69 (5.53%)

19:58
10/17/17
10/17
19:58
10/17/17
19:58
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

19:25
10/17/17
10/17
19:25
10/17/17
19:25
Conference/Events
The Heritage Foundation hosts President Trump »

President Trump speaks at…

SINA

Sina

$114.26

-0.73 (-0.63%)

19:18
10/17/17
10/17
19:18
10/17/17
19:18
Hot Stocks
Aristeia: Sina claims 'inaccurate' and 'misleading' »

Aristeia Capital, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

CLDR

Cloudera

$15.51

0.13 (0.85%)

, HTHIY

Hitachi

$75.56

-0.49 (-0.64%)

18:57
10/17/17
10/17
18:57
10/17/17
18:57
Hot Stocks
Cloudera, Hitachi form strategic partnership »

Cloudera (CLDR) announced…

CLDR

Cloudera

$15.51

0.13 (0.85%)

HTHIY

Hitachi

$75.56

-0.49 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNFP

Pinnacle Financial

$65.15

-1.15 (-1.73%)

18:35
10/17/17
10/17
18:35
10/17/17
18:35
Earnings
Pinnacle Financial reports Q3 adjusted EPS 90c, consensus 74c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Fulton Financial sees FY17 loans & deposits growth mid to high single digits »

Sees FY17 non-interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

EXXI

Energy XXI

$8.59

-0.41 (-4.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Energy XXI provides operational update on Hurricane Nate impact »

Energy XXI provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Fulton Financial cuts Q4 net interest margin view to up 2-6 bp from 3-9 »

Cuts Q4 non-interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

HGV

Hilton Grand Vacations

$39.83

0.05 (0.13%)

17:45
10/17/17
10/17
17:45
10/17/17
17:45
Hot Stocks
Hilton Grand Vacations acquires Sunrise Lodge, terms not disclosed »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

PRGX

PRGX Global

$6.80

0.05 (0.74%)

, KR

Kroger

$20.48

0.04 (0.20%)

17:42
10/17/17
10/17
17:42
10/17/17
17:42
Hot Stocks
PRGX Global signs multi-year technology services contract with Kroger »

PRGX Global (PRGX) signed…

PRGX

PRGX Global

$6.80

0.05 (0.74%)

KR

Kroger

$20.48

0.04 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 14

    Dec

UBFO

United Security Bank

$9.50

-0.05 (-0.52%)

17:38
10/17/17
10/17
17:38
10/17/17
17:38
Earnings
United Security Bank reports Q3 EPS 16c versus 12c in year-ago period »

Reports Q3 NII $8.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSH

Union Bankshares

$35.32

-0.18 (-0.51%)

, XBKS

Xenith Bankshares

$32.77

-0.07 (-0.21%)

17:35
10/17/17
10/17
17:35
10/17/17
17:35
Hot Stocks
Xenith Bankshares merger into Union Bankshares receives regulatory approval »

Union Bankshares (UBSH)…

UBSH

Union Bankshares

$35.32

-0.18 (-0.51%)

XBKS

Xenith Bankshares

$32.77

-0.07 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

OMAB

OMA Airports

$41.34

0.28 (0.68%)

17:35
10/17/17
10/17
17:35
10/17/17
17:35
Hot Stocks
OMA Airports reports Q3 terminal passenger traffic up 1.3% »

Aeronautical revenues per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$146.54

-0.29 (-0.20%)

17:34
10/17/17
10/17
17:34
10/17/17
17:34
Earnings
IBM sees $2.8B-$2.9B increase in Q4 sales from Q3 »

Sees $300M-$400M boost…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

OMAB

OMA Airports

$41.34

0.28 (0.68%)

17:33
10/17/17
10/17
17:33
10/17/17
17:33
Earnings
OMA Airports reports Q3 EPS 66c, consensus 70c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

17:33
10/17/17
10/17
17:33
10/17/17
17:33
Hot Stocks
Breaking Hot Stocks news story on Select Comfort »

Select Comfort says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

, IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: IBM…

IBM

IBM

$146.54

-0.29 (-0.20%)

IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

SSKN

STRATA Skin Sciences

$1.75

-0.04 (-2.23%)

HCLP

Hi-Crush Partners

$8.95

0.25 (2.87%)

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

NAVI

Navient

$12.20

0.47 (4.01%)

CREE

Cree

$29.34

0.06 (0.20%)

AKTX

Akari Therapeutics

$6.40

-0.08 (-1.23%)

MOBL

MobileIron

$3.80

-0.1 (-2.56%)

FOGO

Fogo De Chao

$12.05

0.1 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 22

    Oct

  • 01

    Nov

  • 15

    Nov

  • 18

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
IBM sees increase in gross margin of 2.5 points from Q3 to Q4 »

Says not yet feeling full…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

PAYX

Paychex

$62.90

-0.55 (-0.87%)

17:31
10/17/17
10/17
17:31
10/17/17
17:31
Syndicate
Breaking Syndicate news story on Paychex »

Paychex files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

VZ

Verizon

$48.40

0.31 (0.64%)

17:24
10/17/17
10/17
17:24
10/17/17
17:24
Hot Stocks
FCC settles New York City E-rate investigation with Verizon »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

17:20
10/17/17
10/17
17:20
10/17/17
17:20
Hot Stocks
Breaking Hot Stocks news story on Select Comfort »

Select Comfort expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

17:17
10/17/17
10/17
17:17
10/17/17
17:17
Hot Stocks
IBM: Global business services signings up for 3rd consecutive quarter »

Says cognitive solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.